Advertisement

Vaccine Marketing

Chapter
First Online:
  • 5.5k Downloads
Part of the International Series in Quantitative Marketing book series (ISQM, volume 20)

Abstract

Long perceived as an unattractive segment of the pharmaceutical industry, most of the leading firms have stepped up vaccine investments in recent years. Unlike mainstream pharmaceuticals, vaccines generally treat healthy individuals, most are administered only once or very infrequently during a life time, and they engender positive externalities, because vaccinated individuals reduce the risk of transmission to unvaccinated persons, leading authorities to mandate some vaccinations. Resistance to vaccination may lead to immunization failure and disease resurgence.

The public and private market each account for about one-half of the global vaccine market in value. Bringing new vaccines to market requires carefully orchestrated programs targeting the multiple types of customers. For example, in parallel with the clinical development program designed to obtain FDA approval for its HPV vaccine Gardasil, Merck developed health-economic evidence to obtain a positive recommendation for vaccination and public financing. Physician educational programs and unbranded DTC campaigns were started many months prior to launch. Following FDA approval and positive vaccination and public financing recommendations, Merck developed market access programs targeted at states and private insurers, and launched branded physician and DTC campaigns.

Successful global diffusion of a vaccine generally requires the development of a tiered pricing policy which takes country differences in per capita income into account.

A successful launch often creates new problems for vaccine marketers. They must maintain the motivation to engage in and pay for vaccination despite the quasi-disappearance of the disease. And they must combat anti-vaccination information claiming that the vaccine is the cause of serious side effects.

Keywords

Vaccine Manufacturer Anticipate Regret Preventive Vaccine Vaccination Intention Vaccination Behavior 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Aaker DA (2004) Brand portfolio strategy. Free Press, New York, NYGoogle Scholar
  2. Abrevaya J, Mulligan K (2011) Effectiveness of state-level vaccination mandates: evidence from the varicella vaccine. J Health Econ 30(5):966–976Google Scholar
  3. Adult Immunization Working Group to the National Vaccine Advisory Committee (2011) Adult immunization: complex challenges and recommendations for improvement. Draft report v2.0. http://www.hhs.gov/nvpo/nvac/subgroups/wg_report_v2_25feb2011.pdf. Accessed 22 Aug 2011
  4. Ajzen I (1988) Attitudes, personality, and behavior. Dorsey, Chicago, ILGoogle Scholar
  5. Ajzen I (1991) The theory of planned behavior. Organ Behav Hum Decis Process 50:179–211Google Scholar
  6. Ajzen I, Fishbein M (2005) The influence of attitudes on behavior. In: Albarracin D, Johnson BT, Zanna MP (eds) The handbook of attitudes. Lawrence Erlbaum, Mahwah, NJ, pp 173–221Google Scholar
  7. Allen JD, Mohllajee AP, Shelton RC, Othus MKD, Fontenot HB, Hanna R (2009) Stage of adoption of the human papillomavirus vaccine among college women. Prev Med 48(5):420–425Google Scholar
  8. Allen JD, Othus MK, Shelton RC, Li Y, Norman N, Tom L et al (2010) Parental decision making about the HPV vaccine. Cancer Epidemiol Biomarkers Prev 19(9):2187–2198Google Scholar
  10. Angelmar R, Angelmar S, Kane L (2007) Building strong condition brands. J Med Mark 7(4):341–351Google Scholar
  11. Anonymous (2010) Fighting swine flu fatigue with weird marketing: officials try human billboards, night club promotions to spark interest. Associated Press. http://www.msnbc.msn.com/id/35467666/ns/health-cold_and_flu/t/fighting-swine-flu-fatigue-weird-marketing/#. Accessed 28 Aug 2011Google Scholar
  12. Anonymous (2011) Background information to GAVI alliance’s draft vaccine supply and procurement strategy for the period 2011–2015. http://www.gavialliance.org/library/gavi-documents/supply-procurement/. Accessed 26 Aug 2011
  13. Applebaum M (2007) Life gard. Brandweek 48(36):34–37Google Scholar
  14. Appleby J (2004) Nasal FluMist overcomes obstacles to reach public. USA Today, 6 JanGoogle Scholar
  15. Askelson NM, Campo S, Lowe JB, Smith S, Dennis LK, Andsager J (2010) Using the theory of planned behavior to predict mothers’ intentions to vaccinate their daughters against HPV. J Sch Nurs 26(3):194–202Google Scholar
  16. Averhoff F, Linton L, Peddecord KM, Edwards C, Wang W, Fishbein D (2004) A middle school immunization law rapidly and substantially increases immunization coverage among adolescents. Am J Public Health 94(6):978–984Google Scholar
  17. Balfour L, Corace K, Tasca GA, Tremblay C, Routy JP, Angel JB (2010) Altruism motivates participation in a therapeutic HIV vaccine trial (CTN 173). AIDS Care 22(11):1403–1409Google Scholar
  18. Bardenheier B, Gonzalez IM, Washington ML, Bell BP, Averhoff F, Massoudi MS et al (2003) Parental knowledge, attitudes, and practices associated with not receiving hepatitis a vaccine in a demonstration project in butte county, California. Pediatrics 112(4):269–274Google Scholar
  19. Baron D (2008) Responsible lobbying? No. case P-57. Stanford Graduate School of Business, Stanford, CAGoogle Scholar
  20. Bean SJ (2011) Emerging and continuing trends in vaccine opposition website content. Vaccine 29(10):1874–1880Google Scholar
  21. Becker M (1974) The health belief model and sick role behavior. Health Educ Monogr 2:409–419Google Scholar
  22. Becker MH, Drachman RH, Kirscht JP (1974) A new approach to explaining sick-role behavior in low-income populations. Am J Public Health 64(3):205–216Google Scholar
  23. Benatar S, Howell E, Bovbjerg RR (2010) Universal purchasing of childhood vaccines in New York state: a feasibility assessment. The Urban Institute. http://www.urban.org/uploadedpdf/412235-Universal-Purchasing.pdf. Accessed 18 Aug 2011
  24. Benkimoun P (2011) Le retour inattendu de la rougeole en Europe. Le Monde, 25 MarGoogle Scholar
  25. Berndt ER, Denoncourt RN, Warner AC (2009) U.S. markets for vaccines: characteristics, case studies, and controversies. AEI, Washington, DCGoogle Scholar
  26. Betsch C, Wicker S (2012) E-health use, vaccination knowledge and perception of own risk: drivers of vaccination uptake in medical students. Vaccine 30(6):1143–1148Google Scholar
  27. Betsch C, Renkewitz F, Betsch T, Ulshöfer C (2010) The influence of vaccine-critical websites on perceiving vaccination risks. J Health Psychol 15(3):446–455Google Scholar
  28. Betsch C, Ulshöfer C, Renkewitz F, Betsch T (2011) The influence of narrative v. statistical information on perceiving vaccination risks. Med Decis Making 31(5):742–753Google Scholar
  29. Beutels P, Scuffham PA, MacIntyre CR (2008) Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 8(11):727–733Google Scholar
  30. Bigongiari J (2010) Expiration date for 40 million H1N1 doses passes. http://vaccinenewsdaily.com/news/213605-expiration-date-for-40-million-h1n1-doses-passes. Accessed 19 Aug 2011
  31. Bish A, Yardley L, Nicoll A, Michie S (2011) Factors associated with uptake of vaccination against pandemic influenza: a systematic review. Vaccine 29(38):6472–6484Google Scholar
  32. Bogaards JA, Coupe VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J (2011) Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 22(4):505–515Google Scholar
  33. Brehm SS, Brehm JW (1981) Psychological reactance: a theory of freedom and control. Academic, New York, NYGoogle Scholar
  34. Brewer NT, Cuite CL, Herrington JE, Weinstein ND (2004) Risk perceptions and their relation to risk behavior. Ann Behav Med 27(2):125–130Google Scholar
  35. Brewer NT, Chapman GB, Gibbons FX, Gerrard M, McCaul KD, Weinstein ND (2007) Meta-analysis of the relationship between risk perception and health behavior: the example of vaccination. Health Psychol 26(2):136–145Google Scholar
  36. Brewer NT, Gottlieb SL, Reiter PL, McRee AL, Liddon N, Markowitz L et al (2010) Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis 38(3):197–204Google Scholar
  37. Brien S, Kwong JC, Buckeridge DL (2012) The determinants of 2009 pandemic A/H1N1 influenza vaccination: a systematic review. Vaccine 30(7):1255–1264Google Scholar
  38. Briones R, Nan X, Madden K, Waks L (2012) When vaccines go viral: an analysis of HPV vaccine coverage on YouTube. Health Commun 27(5):478–485Google Scholar
  39. Brown DS, Johnson FR, Poulos C, Messonnier ML (2010) Mothers’ preferences and willingness to pay for vaccinating daughters against human papillomavirus. Vaccine 28(7):1702–1708Google Scholar
  40. Bryson M, Duclos P, Jolly A, Cakmak N (2010) A global look at national immunization technical advisory groups. Vaccine 28(Suppl 1):A13–A17Google Scholar
  41. Business Insights (2009) The vaccines market outlook to 2014. Business Insights Ltd., DundeeGoogle Scholar
  42. Butler D (2010) Vaccine offers meningitis hope. Nature 468(7321):143Google Scholar
  43. Calkins T (2004) MedImmune: FluMist introduction. Case study. Kellogg School of Management, Northwestern University, Evanston, ILGoogle Scholar
  44. Campbell CM, Kirmani A (2008) I know what you’re doing and why you’re doing it: the use of persuasion knowledge model in consumer research. In: Haugtvedt PC, Herr MP, Kardes RF (eds) Handbook of consumer psychology. Lawrence Erlbaum Associates, New York, NY, pp 549–573Google Scholar
  45. Campos-Outcalt D, Jeffcott-Pera M, Carter-Smith P, Schoof BK, Young HF (2010) Vaccines provided by family physicians. Ann Fam Med 8(6):507–510Google Scholar
  46. Caplan A (2011) Vaccination: facts alone do not policy make. Health Aff 30(6):1205–1207Google Scholar
  47. Cates JR, Shafer A, Carpentier FD, Reiter PL, Brewer NT, McRee AL et al (2010) How parents hear about human papillomavirus vaccine: implications for uptake. J Adolesc Health 47(3):305–308Google Scholar
  48. Centers for Disease Control and Prevention (2011) National and state vaccination coverage among children aged 19–35 months—United States, 2010. Morb Mortal Wkly Rep 60(34):1157–1163Google Scholar
  49. Chapman GB, Coups EJ (2006) Emotion and preventive health behavior: worry, regret, and influenza vaccination. Health Psychol 25(1):82–90Google Scholar
  50. Chor JSY, Pada SK, Stephenson I, Goggins WB, Tambyah PA, Clarke TW et al (2011) Seasonal influenza vaccination predicts pandemic H1N1 vaccination uptake among healthcare workers in three countries. Vaccine 29(43):7364–7369Google Scholar
  51. Chow SN, Soon R, Park JS, Pancharoen C, Qiao YL, Basu P et al (2010) Knowledge, attitudes, and communication around human papillomavirus (HPV) vaccination amongst urban Asian mothers and physicians. Vaccine 28(22):3809–3817Google Scholar
  52. Cialdini RB (2009) Influence: science and practice, 5th edn. Pearson Education, Boston, MAGoogle Scholar
  53. Clark SJ, Cowan AE, Wortley PM (2009) Influenza vaccination attitudes and practices among US registered nurses. Am J Infect Control 37(7):551–556Google Scholar
  54. Clark SJ, Cowan AE, Freed GL (2011) Private-sector vaccine purchase costs and insurer payments: a disincentive for using combination vaccines? Hum Vaccin 7(4):426–428Google Scholar
  55. Coleman MS, Lindley MC, Ekong J, Rodewald L (2009) Net financial gain or loss from vaccination in pediatric medical practices. Pediatrics 124:S472–S491Google Scholar
  56. Connolly T, Reb J (2003) Omission bias in vaccination decisions: where’s the “omission”? Where’s the “bias”? Organ Behav Hum Decis Process 91(2):186Google Scholar
  57. Conway MD, Rizzuto CD, Weiss LM (2008) A better way to speed the adoption of vaccines. The McKinsey Quarterly, Aug. http://www.who.int/immunization/stakeholders/mckinsey_speeding_vaccine_adoption.pdf, accessed July 4, 2013
  58. Cook AG (2006) Forecasting for the pharmaceutical industry. Gower Publishing, AldershotGoogle Scholar
  59. Daley MF, Crane LA, Beaty BL, Barrow J, Pearson K, Stevenson JM, Berman S, Kempe A (2005) Provider adoption of pneumococcal conjugate vaccine and the impact of vaccine shortages ambulatory. Pediatrics 5(3):157–164Google Scholar
  60. Daley MF, Liddon N, Crane LA, Beaty BL, Barrow J, Babbel C et al (2006) A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics 118(6):2280Google Scholar
  61. Daley MF, Crane LA, Markowitz LE, Black SR, Beaty BL, Barrow J, Babbel C, Gottlieb SL, Liddon N, Stokley S, Dickinson LM, Kempe A (2010) Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics 126(3):425–433Google Scholar
  62. Danzon PM, Pereira NS (2011) Vaccine supply: effects of regulation and competition. Int J Econ Bus 18(2):239–271Google Scholar
  63. Danzon PM, Towse A, Mulcahy AW (2011) Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. Health Aff 30(8):1529–1538Google Scholar
  64. Deer B (2011) How the case against the MMR vaccine was fixed. BMJ 342Google Scholar
  65. Dekimpe MG, Hanssens DM (1995) Empirical generalizations about market evolution and stationarity. Mark Sci 14(3):G109–G121Google Scholar
  66. Dekker AH (2006) Fostering acceptance of human papillomavirus vaccines. J Am Osteopath Assoc 106(3 Suppl 1):S14–S18Google Scholar
  67. Department of Health (2011) The seasonal influenza immunisation programme. Consultation: a review of the procurement of seasonal flu vaccine. Department of Health, UK. http://consultations.dh.gov.uk/. Accessed 23 Aug 2011
  68. DeRoeck D, Bawazir SA, Carrasco P, Kaddar M, Brooks A, Fitzsimmons J et al (2006) Regional group purchasing of vaccines: review of the pan American health organization EPI revolving fund and the gulf cooperation council group purchasing program. Int J Health Plann Manage 21(1):23–43Google Scholar
  69. Dhalla S, Poole G (2011) Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. AIDS Care 23(11):1430–1447Google Scholar
  70. Downs JS, de Bruin WB, Fischhoff B (2008) Parents’ vaccination comprehension and decisions. Vaccine 26(12):1595–1607Google Scholar
  71. Doyle J, Baumgartner J, Bell J (2010a) HPV vaccine coverage and adoption across the United States. Value Health 13(3):A47Google Scholar
  72. Doyle J, Baumgartner J, Bell J (2010b) Meningitis vaccine coverage and adoption across the United States. Value Health 13(3):A194Google Scholar
  73. Dube E, Fannie D, Vladimir G, Julie BA, Chantal S, France L, Francois BD, Shelly M, Ian G, Nicole B (2011) A(H1N1) pandemic influenza and its prevention by vaccination: paediatricians’ opinions before and after the beginning of the vaccination campaign. BMC Public Health 2011:11(128)Google Scholar
  74. Duclos P, Okwo-Bele JM, Salisbury D (2011) Establishing global policy recommendations: the role of the strategic advisory group of experts on immunization. Expert Rev Vaccines 10(2):163–173Google Scholar
  75. Endrich MM, Blank PR, Szucs TD (2009) Influenza vaccination uptake and socioeconomic determinants in 11 European countries. Vaccine 27(30):4018–4024Google Scholar
  76. Epstude K, Roese NJ (2008) The functional theory of counterfactual thinking. Pers Soc Psychol Rev 12(2):168–192Google Scholar
  77. Eskola J, Kilpi T (2011) Public–private collaboration in vaccine research. Lancet 378(9789):385–386Google Scholar
  78. European Commission (2009) Pharmaceutical sector inquiry final report. European Commission, BrusselsGoogle Scholar
  79. Extance A (2011) Cell-based flu vaccines ready for US prime time. Nat Rev Drug Discov 10:246Google Scholar
  80. Fine PE, Clarkson JA (1986) Individual versus public priorities in the determination of optimal vaccination policies. Am J Epidemiol 124(6):1012–1020Google Scholar
  81. Fishbein M, Ajzen I (1975) Belief, attitude, intention, and behavior: an introduction to theory and research. Addison-Wesley, Reading, MAGoogle Scholar
  82. Flood EM, Rousculp MD, Ryan KJ, Beusterien KM, Divino VM, Toback SL et al (2010) Parents’ decision-making regarding vaccinating their children against influenza: a web-based survey. Clin Ther 32(8):1448–1467Google Scholar
  83. Frank RG (2001) Prescription drug prices: why do some pay more than others do? Health Aff 20(2):115–128Google Scholar
  84. Freed GL, Cowan AE (2002) State-level perspectives on vaccine purchase financing. http://www.iom.edu/~/media/Files/Activity%20Files/Disease/VaccineFinancing/FreedandCowanBackgroundPaper.pdf. Accessed 21 Aug 2011
  85. Freed GL, Cowan AE, Clark SJ (2008a) Primary care physician perspectives on reimbursement for childhood immunizations. Pediatrics 122(6):1319–1324Google Scholar
  86. Freed GL, Cowan AE, Gregory S, Clark SJ (2008b) Variation in provider vaccine purchase prices and payer reimbursement. Pediatrics 122(6):1325–1331Google Scholar
  87. Freed GL, Clark SJ, Butchart AT, Singer DC, Davis MM (2010) Parental vaccine safety concerns in 2009. Pediatrics 125(4):654–659Google Scholar
  88. Freed GL, Clark SJ, Butchart AT, Singer DC, Davis MM (2011a) Sources and perceived credibility of vaccine-safety information for parents. Pediatrics 127(Suppl 1):S107–S112Google Scholar
  89. Freed GL, Clark SJ, Cowan AE, Coleman MS (2011b) Primary care physician perspectives on providing adult vaccines. Vaccine 29(9):1850–1854Google Scholar
  90. Funk S, Salathe M, Jansen VA (2010) Modelling the influence of human behaviour on the spread of infectious diseases: a review. J R Soc Interface 7(50):1247–1256Google Scholar
  91. Galarce EM, Minsky S, Viswanath K (2011) Socioeconomic status, demographics, beliefs and A(H1N1) vaccine uptake in the United States. Vaccine 29(32):5284–5289Google Scholar
  92. Gershoff AD, Koehler JJ (2011) Safety first? The role of emotion in safety product betrayal aversion. J Consum Res 38(1):140–150Google Scholar
  93. Gessner BD, Duclos P, DeRoeck D, Nelson EAS (2010) Informing decision makers: experience and process of 15 national immunization technical advisory groups. Vaccine 28(Suppl 1):A1–A5Google Scholar
  94. Ghemawat P (2010) Strategy and the business landscape, 3rd edn. Pearson Education, Upper Saddle River, NJGoogle Scholar
  95. Gidengil CA, Rusinak D, Allred NJ, Luff D, Lee GM, Lieu TA (2009) Financial barriers to implementing combination vaccines: perspectives from pediatricians and policy makers. Clin Pediatr 48(5):539–547Google Scholar
  96. Gidengil CA, Dutta-Linn MM, Messonnier ML, Rusinak D, Lieu TA (2010) Financial barriers to the adoption of combination vaccines by pediatricians. Arch Pediatr Adolesc Med 164(12):1138–1144Google Scholar
  97. Godin G, Vezina-Im LA, Naccache H (2010) Determinants of influenza vaccination among healthcare workers. Infect Control Hosp Epidemiol 31(7):689–693Google Scholar
  98. Godlee F, Smith J, Marcovitch H (2011) Wakefield’s article linking MMR vaccine and autism was fraudulent. BMJ 342Google Scholar
  99. Gust D, Brown C, Sheedy K, Hibbs B, Weaver D, Nowak G (2005) Immunization attitudes and beliefs among parents: beyond a dichotomous perspective. Am J Health Behav 29(1):81–92Google Scholar
  100. Gust DA, Kennedy A, Wolfe S, Sheedy K, Nguyen C, Campbell S (2008) Developing tailored immunization materials for concerned mothers. Health Educ Res 23(3):499–511Google Scholar
  101. Gust DA, Kennedy A, Weber D, Evans G, Kong Y, Salmon D (2009) Parents questioning immunization: evaluation of an intervention. Am J Health Behav 33(3):287–298Google Scholar
  102. Guyon, J. (2005). The coming storm over a cancer vaccine. Fortune, 31 OctGoogle Scholar
  103. Haas M, Ashton T, Blum K, Christiansen T, Conis E, Crivelli L et al (2009) Drugs, sex, money and power: an HPV vaccine case study. Health Policy 92(2):288–295Google Scholar
  104. Hall AJ (2010) The United Kingdom joint committee on vaccination and immunisation. Vaccine 28(Suppl 1):A54–A57Google Scholar
  105. Harold R, Odqvist F (2011) Achieving launch excellence: a question of penetrating the dynamic market. Pharmaceutical Commerce, July/Aug. http://pharmaceuticalcommerce.com/index.php?pg=business_finance&articleid=2528, accessed July 4, 2013Google Scholar
  106. IMS Health (2011) Total unaudited and audited global pharmaceutical market 2003–2010. http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-line%20Market%20Data/2010%20Top-line%20Market%20Data/Total_Market_2003-2010.pdf. Accessed 14 Jan 2012
  107. Healy CM, Pickering LK (2011) How to communicate with vaccine-hesitant parents. Pediatrics 127(Suppl 1):S127–S133Google Scholar
  108. Hershey JC, Asch DA, Thumasathit T, Meszaros J, Waters VV (1994) The roles of altruism, free riding, and bandwagoning in vaccination decisions. Organ Behav Hum Decis Process 59(2):177–187Google Scholar
  109. Herskovitz B (2007) Brand of the year. Pharmaceutical Executive, FebGoogle Scholar
  110. Humiston SG, Albertin C, Schaffer S, Rand C, Shone LP, Stokley S et al (2009) Health care provider attitudes and practices regarding adolescent immunizations: a qualitative study. Patient Educ Couns 75(1):121–127Google Scholar
  111. Hunsaker J, Veselovskiy G, Gazmararian JA (2009) Health insurance plans and immunization: assessment of practices and policies, 2005–2008. Pediatrics 124(Suppl 5):S532–S539Google Scholar
  112. Hurley LP, Lindley MC, Harpaz R, Stokley S, Daley MF, Crane LA, Dong F, Beaty BL, Tan L, Babbel C, Dickinson LM, Kempe A (2010) Barriers to the use of herpes zoster vaccine. Ann Intern Med 152(9):555–560Google Scholar
  113. Ibuka Y, Chapman GB, Meyers LA, Li M, Galvani AP (2010) The dynamics of risk perceptions and precautionary behavior in response to 2009 (H1N1) pandemic influenza. BMC Infect Dis 10(1):296Google Scholar
  114. International AIDS Vaccine Initiative (IAVI) (2008a) WHO’s key normative processes and institutions for vaccines: a primer. Report Nr. 15. http://www.iavi.org/Information-Center/Publications/Pages/WHO’s-Key-Normative-Processes-and-Institutions-for-Vaccines.aspx, accessed July 4, 2013
  115. International AIDS Vaccine Initiative (IAVI) (2008b) Procurement and pricing of new vaccines for developing countries. Policy Brief Nr. 16. http://www.iavi.org/Information-Center/Publications/Pages/Procurementand-Pricing-of-New-Vaccines-for-Developing-Countries.aspx, accessed July 4, 2013
  116. IOM (Institute of Medicine) (2003) Financing vaccines in the 21st century: assuring access and availability. National Academies, Washington, DCGoogle Scholar
  117. IOM (Institute of Medicine) (2010) Priorities for the national vaccine plan. National Academies, Washington, DCGoogle Scholar
  118. IOM (Institute of Medicine) (2011) Adverse effects of vaccines: evidence and causality. The National Academies, Washington, DCGoogle Scholar
  119. Ishibashi KL, Koopmans J, Curlin FA, Alexander KA, Ross LF (2008) Paediatricians’ attitudes and practices towards HPV vaccination. Acta Paediatr 97(11):1550–1556Google Scholar
  120. Jacobson VJ, Szilagyi P (2005) Patient reminder and patient recall systems to improve immunization rates. Cochrane Database Syst Rev 3(3):CD003941Google Scholar
  121. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L (2009) Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, national immunization survey-adult 2007. Prev Med 48(5):426–431Google Scholar
  122. Kahan D, Braman D, Cohen G, Gastil J, Slovic P (2010) Who fears the HPV vaccine, who doesn’t, and why? An experimental study of the mechanisms of cultural cognition. Law Hum Behav 34(6):501–516Google Scholar
  123. Kahn JA, Zimet GD, Bernstein DI, Riedesel JM, Lan D, Huang B et al (2005) Pediatricians’ intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health 37(6):502–510Google Scholar
  124. Kata A (2010) A postmodern Pandora’s box: anti-vaccination misinformation on the internet. Vaccine 28(7):1709–1716Google Scholar
  125. Kata A (2012) Anti-vaccine activists, web 2.0, and the postmodern paradigm—an overview of tactics and tropes used online by the anti-vaccination movement. Vaccine 30(25):3778–3789Google Scholar
  126. Kaufmann JR, Miller R, Cheyne J (2011) Vaccine supply chains need to be better funded and strengthened, or lives will be at risk. Health Aff 30(6):1113–1121Google Scholar
  127. Keane MT, Walter MV, Patel BI, Moorthy S, Stevens RB, Bradley KM et al (2005) Confidence in vaccination: a parent model. Vaccine 23(19):2486–2493Google Scholar
  128. Keller KL (2008) Strategic brand management: building, measuring, and managing brand equity, 3rd edn. Pearson Education, Upper Saddle River, NJGoogle Scholar
  129. Kempe A, Daley MF, Parashar UD, Crane LA, Beaty BL, Stokley S, Barrow J, Babbel C, Dickinson LM, Widdowson M-A, Alexander JP, Berman S (2007) Will pediatricians adopt the new rotavirus vaccine? Pediatrics 119(1):1–10Google Scholar
  130. Kenkel DS (2000) Prevention. In: Culyer AJ, Newhouse JP (eds) Handbook of health economics, vol 1B. Elsevier, Amsterdam, pp 1675–1720Google Scholar
  131. Kennedy A, Basket M, Sheedy K (2011a) Vaccine attitudes, concerns, and information sources reported by parents of young children: results from the 2009 HealthStyles survey. Pediatrics 127(Suppl 1):S92–S99Google Scholar
  132. Kennedy A, LaVail K, Nowak G, Basket M, Landry S (2011b) Confidence about vaccines in the United States: understanding parents’ perceptions. Health Aff 30(6):1151–1159Google Scholar
  133. Kennedy A, Stokley S, Curtis CR, Gust D (2012) Limited awareness of vaccines recommended for adolescents and other results from two national consumer health surveys in the United States. J Adolesc Health 50(2):198–200Google Scholar
  134. KFF (2011) Fact sheet. The HPV vaccine: access and use in the U.S. http://kaiserfamilyfoundation.files.wordpress.com/2013/01/7602-03.pdf. Accessed 4 July 2013
  135. Kharbanda EO, Stockwell MS, James C, Natarajan K, Rickert VI (2010) Changes in tdap and MCV4 vaccine coverage following enactment of a statewide requirement of tdap vaccination for entry into sixth grade. Am J Public Health 100(9):1635–1640Google Scholar
  136. Koehler JJ, Gershoff AD (2003) Betrayal aversion: when agents of protection become agents of harm. Organ Behav Hum Decis Process 90(2):244Google Scholar
  137. Kremer M (2001a) Creating markets for new vaccines: part I: rationale. In: Stern S (ed) Innovation policy and the economy, vol 1. MIT for the National Bureau of Economic Research, London, pp 35–72Google Scholar
  138. Kremer M (2001b) Creating markets for new vaccines: part II: design issues. In: Stern S (ed) Innovation policy and the economy, vol 1. MIT for the National Bureau of Economic Research, London, pp 73–118Google Scholar
  139. Kresse H, Shah M (2010) Strategic trends in the vaccine market. Nat Rev Drug Discov 9:913–914Google Scholar
  140. Kyle MK, Ridley DB (2007) Would greater transparency and uniformity of health care prices benefit poor patients? Health Aff 26(5):1384–1391Google Scholar
  141. Lantos JD, Jackson MA, Opel DJ, Marcuse EK, Myers AL, Connelly BL (2010) Controversies in vaccine mandates. Curr Probl Pediatr Adolesc Health Care 40(3):38–58Google Scholar
  142. Larson HJ, Cooper LZ, Eskola J, Katz SL, Ratzan S (2011) Addressing the vaccine confidence gap. Lancet 378(9790):526–535Google Scholar
  143. Laurent-Ledru V, Thomson A, Monsonego J (2011) Civil society: a critical new advocate for vaccination in Europe. Vaccine 29(4):624–628Google Scholar
  144. Leask J, Chapman S, Cooper Robbins SC (2010) “All manner of ills”: the features of serious diseases attributed to vaccination. Vaccine 28(17):3066–3070Google Scholar
  145. Lefevere E, Hens N, De Smet F, Van Damme P (2011) Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007–2009: a cox regression model. BMC Public Health 11(1):470Google Scholar
  146. Levine OS, Bloom DE, Cherian T, de Quadros C, Sow S, Wecker J et al (2011) The future of immunisation policy, implementation, and financing. Lancet 378(9789):439–448Google Scholar
  147. Lichtenberg FR (2011) Pharmaceutical companies’ variation of drug prices within and among countries can improve long-term social well-being. Health Aff 30(8):1539–1544Google Scholar
  148. Lieu TA, McGuire TG, Hinman AR (2005) Overcoming economic barriers to the optimal use of vaccines. Health Aff 24(3):666–679Google Scholar
  149. Light DW, Andrus JK, Warburton RN (2009) Estimated research and development costs of rotavirus vaccines. Vaccine 27(47):6627–6633Google Scholar
  150. Lindley MC, Shen AK, Orenstein WA, Rodewald LE, Birkhead GS (2009) Financing the delivery of vaccines to children and adolescents: challenges to the current system. Pediatrics 124(Suppl 5):S548–S557Google Scholar
  151. Lydon P, Beyai PL, Chaudhri I, Cakmak N, Satoulou A, Dumolard L (2008) Government financing for health and specific national budget lines: the case of vaccines and immunization. Vaccine 26(51):6727–6734Google Scholar
  152. MacDonald NE, Smith J, Appleton M (2012) Risk perception, risk management and safety assessment: what can governments do to increase public confidence in their vaccine system? Biologicals 40(5):384–388Google Scholar
  153. Maltezou HC, Dedoukou X, Patrinos S, Maragos A, Poufta S, Gargalianos P et al (2010) Determinants of intention to get vaccinated against novel (pandemic) influenza A H1N1 among health-care workers in a nationwide survey. J Infect 61(3):252–258Google Scholar
  154. Marquez-Calderon S, Lopez-Valcarcel BG, Segura A (2009) Medical societies’ recommendations for immunization with human papillomavirus vaccine and disclosure of conflicts of interests. Prev Med 48(5):449–453Google Scholar
  155. Maurer J, Uscher-Pines L, Harris KM (2010a) Perceived seriousness of seasonal and A(H1N1) influenzas, attitudes toward vaccination, and vaccine uptake among U.S. adults: does the source of information matter? Prev Med 51(2):185–187Google Scholar
  156. Maurer J, Uscher-Pines L, Harris KM (2010b) Awareness of government seasonal and 2009 H1N1 influenza vaccination recommendations among targeted US adults: the role of provider interactions. Am J Infect Control 38(6):489–490Google Scholar
  157. McNeil DG Jr (2011) For first time, UNICEF reveals differences in prices it pays drug companies for vaccines. New York Times, 27 MayGoogle Scholar
  158. Miller BL, Kretsinger K, Euler GL, Lu P, Ahmed F (2011) Barriers to early uptake of tetanus, diphtheria and acellular pertussis vaccine (tdap) among adults—United States, 2005–2007. Vaccine 29(22):3850–3856Google Scholar
  159. Millstein SG (1996) Utility of the theories of reasoned action and planned behavior for predicting physician behavior: a prospective analysis. Health Psychol 15(5):398–402Google Scholar
  160. Milstien JB, Kaddar M (2010) The role of emerging manufacturers in access to innovative vaccines of public health importance. Vaccine 28(9):2115–2121Google Scholar
  161. Milstien J, Cardenas V, Cheyne J, Brooks A (2010) WHO policy development processes for a new vaccine: case study of malaria vaccines. Malar J 9:182Google Scholar
  162. Moore GR, Crosby RA, Young A, Charnigo R (2010) Low rates of free human papillomavirus vaccine uptake among young women. Sex Health 7(3):287–290Google Scholar
  163. Morgon PA (2011) Opening doors to the developing world through superior market access strategies. Investor Day, MarGoogle Scholar
  164. Morison LA, Cozzolino PJ, Orbell S (2010) Temporal perspective and parental intention to accept the human papillomavirus vaccination for their daughter. Br J Health Psychol 15(Pt 1):151–165Google Scholar
  165. Moxon ER, Siegrist C (2011) The next decade of vaccines: societal and scientific challenges. Lancet 378(9788):348–359Google Scholar
  166. Myers LB, Goodwin R (2011) Determinants of adults’ intention to vaccinate against pandemic swine flu. BMC Public Health 11(1):15Google Scholar
  167. National Center for Health Statistics (2011) Health, United States, 2010: with special feature on death and dying. National Center for Health Statistics, Hyattsville, MDGoogle Scholar
  168. Nguyen A, Furrer E, Schwalbe N (2011) Market shaping: strategic considerations for a healthy vaccine marketplace. The GAVI Alliance. http://www.gavialliance.org/library/gavi-documents/white-papers/. Accessed 24 Aug 2011
  169. Nicholson MS, Leask J (2012) Lessons from an online debate about measles–mumps–rubella (MMR) immunization. Vaccine 30(25):3806–3812Google Scholar
  170. Nolan TM (2010) The Australian model of immunization advice and vaccine funding. Vaccine 28(Suppl 1):A76–A83Google Scholar
  171. Nordquist G, Wu S (1976) The joint demand for health insurance and preventive medicine. In: Rosett RN (ed) The role of health insurance in the health services sector. National Bureau of Economic Research, New York, NYGoogle Scholar
  172. Offit AP (2011) Deadly choices: how the anti-vaccine movement threatens us all. Basic Books, New York, NYGoogle Scholar
  173. Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N (2009) Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med 360(19):1981–1988Google Scholar
  174. Orenstein WA, Mootrey GT, Pazol K, Hinman AR (2007) Financing immunization of adults in the United States. Clin Pharmacol Ther 82(6):764–768Google Scholar
  175. Palli S, Mehta S, Chatterjee S, Aparasu R (2010) Prevalence and correlates of human papillomavirus vaccination in adolescent girls: results from a national survey of children’s health. Value Health 13(3):A47Google Scholar
  176. Pan American Health Organization (2010) The revolving fund as a cooperation mechanism for immunization programs in the Americas—FAQs. http://new.paho.org/hq/dmdocuments/2010/RevolvingFund_FAQs_ENG.pdf. Accessed 22 Aug 2011
  177. Parikh RK (2008) Fighting for the reputation of vaccines: lessons from American politics. Pediatrics 121(3):621–622Google Scholar
  178. Payaprom Y, Bennett P, Alabaster E, Tantipong H (2011) Using the health action process approach and implementation intentions to increase flu vaccine uptake in high risk Thai individuals: a controlled before-after trial. Health Psychol 30(4):492–500Google Scholar
  179. Petrovic K, Burney S, Fletcher J (2011) The relationship of knowledge, health value and health self-efficacy with men’s intentions to receive the human papillomavirus (HPV) vaccine. J Health Psychol 16(8):1198–1207Google Scholar
  180. Phelps CE (1978) Illness prevention and medical insurance. J Hum Resour 183–207Google Scholar
  181. Philipson T (2000) Economic epidemiology and infectious diseases. In: Culyer AJ, Newhouse JP (eds) Handbook of health economics, vol 1B. Elsevier, The Netherlands, pp 1761–1799Google Scholar
  182. Poland GA, Jacobson RM (2011) The age-old struggle against the antivaccinationists. N Engl J Med 364(2):97–99Google Scholar
  183. Porter M (1980) Competitive strategy. Free Press, New York, NYGoogle Scholar
  184. Prislin R, Dyer JA, Blakely CH, Johnson CD (1998) Immunization status and sociodemographic characteristics: the mediating role of beliefs, attitudes, and perceived control. Am J Public Health 88(12):1821Google Scholar
  185. Rand CM, Shone LP, Albertin C, Auinger P, Klein JD, Szilagyi PG (2007) National health care visit patterns of adolescents: implications for delivery of new adolescent vaccines. Arch Pediatr Adolesc Med 161(3):252–259Google Scholar
  186. Rao N, Mobius MM, Rosenblat T (2007) Social networks and vaccination decisions. Federal Reserve Bank of Boston, Working Papers: 07-1Google Scholar
  187. Raude J, Caille-Brillet al, Setbon M (2010) The 2009 pandemic H1N1 influenza vaccination in France: who accepted to receive the vaccine and why? PLoS Curr 2, RRN1188Google Scholar
  188. ResearchInChina (2011) China human vaccine industry report 2010–2011, Beijing http://www.researchinchina.com/Htmls/Report/2011/6124.html, accessed Jul 4, 2013
  189. Reyna VF (2012) Risk perception and communication in vaccination decisions: a fuzzy-trace theory approach. Vaccine 30(25):3790–3797Google Scholar
  190. Riedesel J, Rosenthal S, Zimet G, Bernstein D, Huang B, Lan D et al (2005) Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol 18(6):391–398Google Scholar
  191. Rivis A, Sheeran P, Armitage CJ (2009) Expanding the affective and normative components of the theory of planned behavior: a meta-analysis of anticipated affect and moral norms. J Appl Soc Psychol 39(12):2985–3019Google Scholar
  192. Roehm ML, Tybout AM (2006) When will a brand scandal spill over, and how should competitors respond? J Mark Res 43(3):366–373Google Scholar
  193. Roese NJ (1997) Counterfactual thinking. Psychol Bull 121(1):133–148Google Scholar
  194. Rogers RW (1975) A protection motivation theory of fear appeals and attitude change. J Psychol 91:93–114Google Scholar
  195. Rogers RW (1983) Cognitive and physiological processes in fear appraisals and attitude change: a revised theory of protection motivation. In: Cacioppo JT, Petty RE (eds) Social psychology: a source book. Guildford, New York, NY, pp 153–176Google Scholar
  196. Rosenbom KA (2010) Developments in UNICEF vaccine procurement. Global Immunization Meeting. http://www.who.int/immunization_delivery/systems_policy/Vaccine_supply_and_pricing.pdf. Accessed 22 Aug 2011
  197. Rosenstock IM (1974) Historical origins of the health belief model. Health Educ Monogr 2:328–335Google Scholar
  198. Rosenthal E (2008) Drug makers’ push leads to cancer vaccines’ fast rise. The New York Times, 20 AugGoogle Scholar
  199. Rosenthal SL, Weiss TW, Zimet GD, Ma L, Good MB, Vichnin MD (2011) Predictors of HPV vaccine uptake among women aged 19–26: importance of a physician’s recommendation. Vaccine 29(5):890–895Google Scholar
  200. Rothman SM, Rothman DJ (2009) Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA 302(7):781–786Google Scholar
  201. Roughead EE, Gilbert AL, Vitry AI (2008) The Australian funding debate on quadrivalent HPV vaccine: a case study for the national pharmaceutical policy. Health Policy 88(2):250–257Google Scholar
  202. Ruijs WL, Hautvast JL, van der Velden K, de Vos S, Knippenberg H, Hulscher ME (2011) Religious subgroups influencing vaccination coverage in the Dutch bible belt: an ecological study. BMC Public Health 11:102Google Scholar
  203. Sahoo A (2010) Vaccines 2010: the world market. Kalorama Information, New York, NYGoogle Scholar
  204. Salmon DA, Moulton LH, Omer SB, DeHart MP, Stokley S, Halsey NA (2005) Factors associated with refusal of childhood vaccines among parents of school-aged children: a case–control study. Arch Pediatr Adolesc Med 159(5):470–476Google Scholar
  205. Salmon DA, Teret SP, MacIntyre CR, Salisbury D, Burgess MA, Halsey NA (2006) Compulsory vaccination and conscientious or philosophical exemptions: past, present, and future. Lancet 367(9508):436–442Google Scholar
  206. Salmon DA, Pan WK, Omer SB, Navar AM, Orenstein W, Marcuse EK et al (2008) Vaccine knowledge and practices of primary care providers of exempt vs. vaccinated children. Hum Vaccin 4(4):286–291Google Scholar
  207. Sandberg T, Conner M (2008) Anticipated regret as an additional predictor in the theory of planned behaviour: a meta-analysis. Br J Soc Psychol 47(4):589–606Google Scholar
  208. Sanofi Pasteur (2009) Vaccine IR seminar, 17th December 2009. http://en.sanofi.com/Images/16351_090817_IR_Seminar_Vaccines.pdf. Accessed 18 Jan 2012
  209. Saxenian H, Cornejo S, Thorien K, Hecht R, Schwalbe N (2011) An analysis of how the GAVI alliance and low- and middle-income countries can share costs of new vaccines. Health Aff 30(6):1122–1133Google Scholar
  210. Schaffer SJ, Humiston SG, Shone LP, Averhoff FM, Szilagyi PG (2001) Adolescent immunization practices: a national survey of US physicians. Arch Pediatr Adolesc Med 155(5):566–571Google Scholar
  211. Scherer FM (2007) An industrial organization perspective on the influenza vaccine shortage. Manage Decis Econ 28(4):393–405Google Scholar
  212. Schönberger K, Grote V, von Kries R, Kalies H (2009) Risikofaktoren für eine verspätete oder nicht erfolgte Masernimpfung bei Kleinkindern. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 52(11):1045–1051Google Scholar
  213. Schoub BD, Ngcobo NJ, Madhi S (2010) The national advisory group on immunization (NAGI) of the republic of South Africa. Vaccine 28(Suppl 1):A31–A34Google Scholar
  214. Schwartz JL (2010) HPV vaccination’s second act: promotion, competition, and compulsion. Am J Public Health 100(10):1841–1844Google Scholar
  215. Senouci K, Blau J, Nyambat B, Coumba Faye P, Gautier L, Da Silva A et al (2010) The supporting independent immunization and vaccine advisory committees (SIVAC) initiative: a country-driven, multi-partner program to support evidence-based decision making. Vaccine 28:A26–A30Google Scholar
  216. Setse RW, Euler GL, Gonzalez-Feliciano AG, Bryan LN, Furlow C, Weinbaum CM, Singleton JA (2011) Influenza vaccination coverage—United States, 2000–2010. Surveillance summaries: morbidity and mortality weekly report. Surveillance Summaries/CDC 60(Suppl), 38–41.Google Scholar
  217. Shearer JC, Stack ML, Richmond MR, Bear AP, Hajjeh RA, Bishai DM (2010) Accelerating policy decisions to adopt haemophilus influenzae type B vaccine: a global, multivariable analysis. PLoS Med 7(3):e1000249Google Scholar
  218. Shefer A, Markowitz L, Deeks S, Tam T, Irwin K, Garland SM et al (2008) Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia. Vaccine 26(Suppl 10):K68–K75Google Scholar
  219. Shen AK, Hunsaker J, Gazmararian JA, Lindley MC, Birkhead GS (2009a) Role of health insurance in financing vaccinations for children and adolescents in the United States. Pediatrics 124(Suppl 5):S522–S531Google Scholar
  220. Shen AK, Rodewald LE, Birkhead GS (2009b) Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States. Pediatrics 124(Suppl 5):S540–S547Google Scholar
  221. Shirvill J (2010) Innovations and opportunities in therapeutic vaccines. Business Insights Ltd., DundeeGoogle Scholar
  222. Shortridge EF, Moore JR, Whitmore H, O’Grady MJ, Shen AK (2011) Policy implications of first-dollar coverage: a qualitative examination from the payer perspective. Public Health Rep 126(3):394–399Google Scholar
  223. Silverman E (2009) The vaccine market grows up: they’re not just for kids anymore. IN VIVO, JulyGoogle Scholar
  224. Skea ZC, Entwistle VA, Watt I, Russell E (2008) ‘Avoiding harm to others’ considerations in relation to parental measles, mumps and rubella (MMR) vaccination discussions—an analysis of an online chat forum. Soc Sci Med 67(9):1382–1390Google Scholar
  225. Smith JC (2010a) The structure, role, and procedures of the U.S. advisory committee on immunization practices (ACIP). Vaccine 28(Suppl 1):A68–A75Google Scholar
  226. Smith PG (2010b) Concepts of herd protection and immunity. Procedia Vaccinol 2(2):134–139Google Scholar
  227. Smith JC, Snider DE, Pickering LK, Advisory Committee on Immunization Practices (2009) Immunization policy development in the United States: the role of the advisory committee on immunization practices. Ann Intern Med 150(1):45–49Google Scholar
  228. Smith J, Lipsitch M, Almond JW (2011a) Vaccine production, distribution, access, and uptake. Lancet 378(9789):428–438Google Scholar
  229. Smith PJ, Humiston SG, Marcuse EK, Zhao Z, Dorell CG, Howes C et al (2011b) Parental delay or refusal of vaccine doses, childhood vaccination coverage at 24 months of age, and the health belief model. Public Health Rep 126(Suppl 2):135–146Google Scholar
  230. Smith-McLallen A, Fishbein M (2008) Predictors of intentions to perform six cancer-related behaviours: roles for injunctive and descriptive norms. Psychol Health Med 13(4):389–401Google Scholar
  231. Snyder CM, Begor W, Berndt ER (2011) Economic perspectives on the advance market commitment for pneumococcal vaccines. Health Aff 30(8):1508–1517Google Scholar
  232. Spier RE (2001) Perception of risk of vaccine adverse events: a historical perspective. Vaccine 20(Suppl 1):S78–S84Google Scholar
  233. Srinivasan S, Bass FM (2000) Cointegration analysis of brand and category sales: stationarity and long-run equilibrium in market shares. Appl Stoch Models Bus Ind 16(3):159–177Google Scholar
  234. Stockwell MS, Rosenthal SL, Sturm LA, Mays RM, Bair RM, Zimet GD (2011) The effects of vaccine characteristics on adult women’s attitudes about vaccination: a conjoint analysis study. Vaccine 29(27):4507–4511Google Scholar
  235. Sutton J (2007) Market share dynamics and the ‘persistence of leadership’ debate. Am Econ Rev 97(1):222–241Google Scholar
  236. Szilagyi, P.G.; Rand, C.M.; McLaurin, J.; Tan, L.; Britto, M.; Francis, A.; Dunne, E.; Rickert, D.; Working Group on Adolescent Vaccination in the Medical Home (2008) Delivering adolescent vaccinations in the medical home: a new era? Pediatrics 121(Suppl 1):S15–S24Google Scholar
  237. Szilagyi PG, Shone LP, Barth R, Kouides RW, Long C, Humiston SG, Jennings J, Bennett NM (2005) Physician practices and attitudes regarding adult immunizations. Prev Med 40(2):152–161Google Scholar
  238. Tan L (2011) Impact of the affordable care act on immunization. American Medical Association, Chicago, IL. http://www.ama-assn.org/resources/doc/public-health/immunization101-tan2.pdf. Accessed 17 Aug 2011
  239. Thomaselli R (2004) FluMist ready for flu shot shortage. Advertising Age, 11 OctGoogle Scholar
  240. Tickner S, Leman PJ, Woodcock A (2007) ‘It’s just the normal thing to do’: exploring parental decision-making about the ‘five-in-one’ vaccine. Vaccine 25(42):7399–7409Google Scholar
  241. Tickner S, Leman PJ, Woodcock A (2010a) The immunisation beliefs and intentions measure (IBIM): predicting parents’ intentions to immunise preschool children. Vaccine 28(19):3350–3362Google Scholar
  242. Tickner S, Leman PJ, Woodcock A (2010b) Parents’ views about pre-school immunization: an interview study in southern England. Child Care Health Dev 36(2):190–197Google Scholar
  243. Timmermans DRM, Henneman L, Hirasing RA, van der Wal G (2005) Attitudes and risk perception of parents of different ethnic backgrounds regarding meningococcal C vaccination. Vaccine 23(25):3329–3335Google Scholar
  244. To KW, Lee S, Chan TO, Lee SS (2010) Exploring determinants of acceptance of the pandemic influenza A (H1N1) 2009 vaccination in nurses. Am J Infect Control 38(8):623–630Google Scholar
  245. Tybout AM, Calder BJ, Sternthal B (1981) Using information processing theory to design marketing strategies. J Mark Res 18(1):73–79Google Scholar
  246. U.S. Department of Health & Human Services (2010) 2010 National vaccine plan. U.S. Department of Health & Human Services, Washington, DCGoogle Scholar
  247. Uddin M, Cherkowski GC, Liu G, Zhang J, Monto AS, Aiello AE (2010) Demographic and socioeconomic determinants of influenza vaccination disparities among university students. J Epidemiol Community Health 64(9):808–813Google Scholar
  248. Usman HR, Kristensen S, Rahbar MH, Vermund SH, Habib F, Chamot E (2010) Determinants of third dose of diphtheria-tetanus-pertussis (DTP) completion among children who received DTP1 at rural immunization centres in Pakistan: a cohort study. Trop Med Int Health 15(1):140–147Google Scholar
  249. Vaux S, Van Cauteren D, Guthmann JP, Le Strat Y, Vaillant V, de Valk H et al (2011) Influenza vaccination coverage against seasonal and pandemic influenza and their determinants in France: a cross-sectional survey. BMC Public Health 11:30Google Scholar
  250. Weinreb, S. L. (2011). For the herd’s sake, vaccinate. The New York Times, December 27Google Scholar
  251. Weinstein ND (2007) Misleading tests of health behavior theories. Ann Behav Med 33(1):1–10Google Scholar
  252. Weinstein ND, Kwitel A, McCaul KD, Magnan RE, Gerrard M, Gibbons FX (2007) Risk perceptions: assessment and relationship to influenza vaccination. Health Psychol 26(2):146–151Google Scholar
  253. WHO (2011). Global immunization data. http://www.who.int/immunization_monitoring/Global_Immunization_Data.pdf. Accessed 18 Jan 2012
  254. WHO, UNICEF, World Bank (2009) State of the world’s vaccines and immunization, 3rd edn. World Health Organization, GenevaGoogle Scholar
  255. Wilson P, Post S, Srinivas S (2007) R & D models: lessons from vaccine history. Working paper no. 14. International AIDS Vaccine Initiative, New York, NYGoogle Scholar
  256. Zhao G, Pechmann C (2007) The impact of regulatory focus on adolescents’ response to antismoking advertising campaigns. J Mark Res 44(4):671–687Google Scholar
  257. Zheng J, Zhou Y, Wang H, Liang X (2010) The role of the China experts advisory committee on immunization program. Vaccine 28(Suppl 1):A84–A87Google Scholar
  258. Zimet GD, Stupiansky NW, Weiss TW, Rosenthal SL, Good MB, Vichnin MD (2011) Influence of patient’s relationship status and HPV history on physicians’ decisions to recommend HPV vaccination. Vaccine 29(3):378–381Google Scholar
  259. Zimmerman RK, Schlesselman JJ, Baird AL, Mieczkowski TA (1997) A national survey to understand why physicians defer childhood immunizations.Arch Pediatr Adolesc Med 151(7):657–664Google Scholar
  260. Zuber PLF, El-Ziq I, Kaddar M, Ottosen AE, Rosenbaum K, Shirey M et al (2011) Sustaining GAVI-supported vaccine introductions in resource-poor countries. Vaccine 29(17):3149–3154Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.INSEADFontainebleauFrance
  2. 2.Franchise & Global Marketing Strategy, Sanofi PasteurLyonFrance

Personalised recommendations

Cite chapter

Buy options